The spectrum of genetic mutations in the BeatAML cohort was broad (Figure 1B), with 34.38% of the CN-AML patients harboring an NPM1 mutation, which formed the largest subgroup, consistent with previous studies (6, 9, 30). Here, NPM1 is linked to acute myeloid leukemia.